Robert Bone, PhD
@robertbone.bsky.social
I do science.
Baseball fanatic, hockey enthusiast, probable beer snob.
Baseball fanatic, hockey enthusiast, probable beer snob.
I look forward to the announcement of the new pope Uncle Baby Billy I
May 8, 2025 at 5:05 PM
I look forward to the announcement of the new pope Uncle Baby Billy I
Reposted by Robert Bone, PhD
What’s the difference between a gov controlling an algorithm, silently eliminating reach for things it doesn’t like, vs the same gov using its power, to demand that the platform remove the things it doesn’t like.?
In China they are overt. With TikTok in the US, they control silently
In China they are overt. With TikTok in the US, they control silently
January 19, 2025 at 5:10 PM
What’s the difference between a gov controlling an algorithm, silently eliminating reach for things it doesn’t like, vs the same gov using its power, to demand that the platform remove the things it doesn’t like.?
In China they are overt. With TikTok in the US, they control silently
In China they are overt. With TikTok in the US, they control silently
Wish I could access my twitter to try to refollow people here.
December 2, 2024 at 9:39 PM
Wish I could access my twitter to try to refollow people here.
I think we can all agree it’s time for Alice In Chains to release another album.
December 2, 2024 at 9:37 PM
I think we can all agree it’s time for Alice In Chains to release another album.
Sharing here & LinkedIn: Curious about some of the insights our team gathers? We recently published on provider insights we gathered centering around CAR T therapy usage in relapsed/refractory multiple myeloma and the impact of CARTITUDE-4 data on CAR T usage. onlinelibrary.wiley.com/doi/10.1002/...
Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myeloma
Introduction Initially approved for the fifth-line or later therapeutic setting, the chimeric antigen receptor (CAR) T-cell regimen ciltacabtagene autoleucel (cilta-cel) was recently approved for se...
onlinelibrary.wiley.com
December 2, 2024 at 9:36 PM
Sharing here & LinkedIn: Curious about some of the insights our team gathers? We recently published on provider insights we gathered centering around CAR T therapy usage in relapsed/refractory multiple myeloma and the impact of CARTITUDE-4 data on CAR T usage. onlinelibrary.wiley.com/doi/10.1002/...
Not that impact factors are the end all, be all, but it’s fitting that eLife won’t be receiving an impact factor because of their acceptance/review policy.
In hindsight, glad the one paper I was on that was submitted here wasn’t published at eLife.
In hindsight, glad the one paper I was on that was submitted here wasn’t published at eLife.
November 15, 2024 at 1:04 PM
Not that impact factors are the end all, be all, but it’s fitting that eLife won’t be receiving an impact factor because of their acceptance/review policy.
In hindsight, glad the one paper I was on that was submitted here wasn’t published at eLife.
In hindsight, glad the one paper I was on that was submitted here wasn’t published at eLife.